<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208948</url>
  </required_header>
  <id_info>
    <org_study_id>DMP 77.1.99</org_study_id>
    <nct_id>NCT01208948</nct_id>
  </id_info>
  <brief_title>Clinical Trial on Alpha Lipoic Acid in Diabetic Macular Edema</brief_title>
  <acronym>RETIPON</acronym>
  <official_title>Alpha Lipoic Acid in the Treatment of Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of alpha lipoic acid (ALA) on the occurrence of diabetic macular
      edema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised, double-blind, placebo controlled multicentre study. Patients were randomised to
      the treatment group with 600 mg ALA per day or the placebo group. At each examination we took
      stereo fundus photographs, HbA1c levels, and performed an ophthalmological examination.
      Primary endpoint of the study was the occurrence of clinically significant macular edema
      (CSME) within a follow-up period of 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of clinically significant macular edema (CSME) within a follow-up period of 2 years</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to CSME development</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Alpha lipoic acid 600 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1,2 dithiolane 3 valeric acid</intervention_name>
    <description>600 mg alpha lipoic acid per day</description>
    <arm_group_label>Alpha lipoic acid 600 mg</arm_group_label>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes type II, mild non proliferative diabetic retinopathy,

          -  Microalbuminuria &gt; 30 mg/L

        Exclusion Criteria:

        Ophthalmic exclusion criteria

          -  severe non-proliferative or proliferative diabetic retinopathy

          -  Macular edema

          -  Eye diseases interfering with the examinations of the fundus such as preretinal
             haemorrhage, cataract, vitreous haemorrhage

          -  Amblyopia

          -  Best corrected visual acuity (VA) over 0.5

          -  Glaucoma

          -  Patients with cataract surgery within a period of three months

          -  Other relevant retinal diseases

          -  Non-authorized interventional therapy of diabetic retinopathy (e.g. laser,
             kryo-coagulation, vitrectomy)

          -  General exclusion criteria

          -  Chronic administration of alpha lipoic acid or of more than five successive days
             during the last twelve months

          -  Known intolerance/hypersensitivity to alpha lipoic acid

          -  Type I diabetes mellitus

          -  Poor metabolic control with HbA1c &gt;10.5 %/dl

          -  Late sequelae of diabetes with organic manifestation (e.g. dialysis in cases of renal
             insufficiency, history of kidney transplantation, creatinine &gt; 1.6 mg/dl)

          -  Poorly controlled arterial hypertension (systolic blood pressure &gt; 160 mmHg and/or
             diastolic blood pressure &gt; 95 mmHg)

          -  Severe disturbances in lipid metabolism (triglycerides &gt; 500 mg/dl or total
             cholesterol &gt; 320 mg/dl)

          -  Unpermitted concomitant medication defined as any medicine with a potential
             interaction with alpha lipoic acid or with the effect of alpha lipoic acid were
             excluded as concomitant medication. These included aldose reductase inhibitors,
             substances promoting blood flow, anticoagulants apart from acetylsalicylic acid 500
             mg/day and short-term treatment of diseases with the normal dose of acetylsalicylic
             acid, chronically and systemically administered corticosteroids, hormonal
             contraceptives

          -  Malignancies or life threatening diseases

          -  Drug or alcohol abuse

          -  Blood donation or blood loss greater than 500 ml) within the last 3 months

          -  Pregnancy or breast feeding

          -  Participation in a clinical trial within the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Michael W Ulbig, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilians - University of Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>September 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2010</study_first_posted>
  <last_update_submitted>September 23, 2010</last_update_submitted>
  <last_update_submitted_qc>September 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Anselm Kampik</name_title>
    <organization>Ludwig-Maximilians-University, Munich</organization>
  </responsible_party>
  <keyword>macular edema</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>prevention alpha lipoic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

